Hepatitis A vaccination options for Australia

Journal of Paediatrics and Child Health

Volumn 39, Issue 2, 2003, Pages 83-87

  MacIntyre, C R ^a   Burgess, M A ^b   Hull, B ^b   McIntyre, P B ^b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b NONE

Author keywords

Hepatitis A; Policy; Vaccination

Indexed keywords

HEPATITIS A VACCINE; MEASLES MUMPS RUBELLA VACCINE;

AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE POLICY; HEALTH PROGRAM; HEPATITIS A; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; VACCINATION;

AUSTRALIA; CHILD, PRESCHOOL; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; MALE; PATIENT COMPLIANCE; POLICY MAKING; PROGRAM EVALUATION; VACCINATION;

EID: 0037340116     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1754.2003.00098.x     Document Type: Review

References (34)

1. McIntyre P, Gidding HF, Gilmour R et al. Vaccine Preventable Diseases and Vaccination Coverage in Australia, 1999-2000. National Centre for Immunisation Research, Sydney, 2002.
2. Dittman S. International congress on viral hepatitis A and B: experience in education and prevention. Vaccine 2000; 18: S1-2.
3. Amin J, Gilbert GL, Escott RG, Heath TC, Burgess MA. Hepatitis A epidemiology in Australia: national seroprevalence and notifications. Med. J. Aust. 2001; 174: 338-41.
4. Ferson MJ, Young LC, Stokes ML. Changing epidemiology of hepatitis A in the 1990s in Sydney, Australia. Epidemiol. Infect. 1998; 121: 631-6.
5. Lopez EL, Del Carmen Xifro M, Torrado LE et al. Safety and immunogenicity of a pediatric formulation of inactivated hepatitis A vaccine in Argentinean children. Pediatr. Infect. Dis. J. 2001; 20: 48-52.
6. Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J. Med. Virol. 2001; 63: 1-7.
7. Lee CY, Huang LM, Lee PI et al. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children. Southeast Asian J. Trop. Med. Public Health 2000; 31: 29-36.
8. Kanra G, Yalcin SS, Ceyhan M, Yurdakok K. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk. J. Pediatr. 2000; 42: 105-8.
9. Chan CY, Lee SD, Yu MI, Wang YJ, Chang FY, Lo KJ. Long-term follow-up of hepatitis A vaccination in children. Vaccine 1999; 17: 369-72.
10. Wiedermann G, Kundi M, Ambrosch F, Safary A, D'Hondt E, Delem A. Inactivated hepatitis A vaccine: long-term antibody persistence. Vaccine 1997; 15: 612-15.
11. Chen XQ, Bulbul M, de Gast GC, van Loon AM, Nalin DR, van Hattum J. Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults. J. Hepatol. 1997; 26: 260-64.
12. Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328-34.
13. Maiwald H, Jilg W, Bock HL, Loscher T, Sonnenburg F. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 1997; 15: 346-8.
14. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann. Intern. Med. 1998; 128: 111-14.
15. Sbarbaro JA. Strategies to improve compliance with therapy. Am. J. Med. 1985; 79: 34-7.
16. Da Villa G. Rationale for the infant and adolescent vaccination programmes in Italy. Vaccine 2000; 18: S31-4.
17. Bonanni P, Colombai R, Gasparini R et al. Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy. Pediatr. Infect. Dis. J. 1999; 18: 677-82.
18. Skinner SR, Imberger A, Nolan T, Lester R, Glover S, Bowes G. Randomised controlled trial of an educational strategy to increase school-based adolescent hepatitis B vaccination. Aust. N. Z. J. Public Health 2000; 24: 298-304.
19. Oman KM, Carnie J, Ruff T. Hepatitis B immunisation coverage of infants born to chronic carrier mothers in Victoria. Aust. N. Z. J. Public Health 1997; 21: 731-4.
20. McIntyre P, Amin J, Gidding H et al. Vaccine preventable diseases and vaccine coverage in Australia, 1993-1998. Commun. Dis. Intell. 2000; Suppl.: v-83.
21. Allard R, Beauchemin J, Bedard L, Dion R, Tremblay M, Carsley J. Hepatitis A vaccination during an outbreak among gay men in Montreal, Canada, 1995-1997. J. Epidemiol. Community Health 2001; 55: 251-6.
22. Irwin DJ, Millership S. Control of a community hepatitis A outbreak using hepatitis A vaccine. Commun. Dis. Public Health 1999; 2: 184-7.
23. Hanna JN, Warnock TH, Shepherd RW, Selvey LA. Fulminant hepatitis A in Indigenous children in north Queensland. Med. J. Aust. 2000; 172: 19-21.
24. Hills SL, Hanna JN. Hepatitis A in north Queensland, 2001. Trop. Public Health Unit Commun. Dis. Control Newsletter 2002; 39: 4.
25. Averhoff F, Shapiro CN, Bell BP et al. Control of hepatitis A through routine vaccination of children. JAMA 2001; 286: 2968-73.
26. Germinario C, Lopalco PL, Chirona M, Da Villa G, Chicanna M. From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience. Vaccine 2000; 18: S83-5.
27. Salleras L, Bruguera M, Buti M, Domingez A. Prospects for vaccination against hepatitis A and B in Catalonia (Spain). Vaccine 2000; 18: S80-82.
28. Green MS, Aharonowitz G, Shohat T, Levine R, Anis E, Slater PE. The changing epidemiology of viral hepatitis A in Israel. Isr. Med. Assoc. J. 2001; 3: 347-51.
29. Anis E, Leventhal A, Roitman M, Slater PE. Introduction of routine hepatitis A immunization in Israel - the first in the world. Harefuah 2000; 138: 177-80, 272.
30. Das A. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Hepatology 1999; 29: 548-52.
31. Saab S, Martin P, Yee HF Jr. A simple cost-decision analysis model comparing two strategies for hepatitis A vaccination. Am. J. Med. 2000; 109: 241-4.
32. Arnal JM, Frisas O, Garuz R, Antonanzas F. Cost effectiveness of hepatitis A virus immunisation in Spain. Pharmacoeconomics 1997; 12: 361-73.
33. Jacobs RJ, Meyerhoff AS. Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. Prev. Med. 2001; 33: 639-45.
34. Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch. Pediatr. Adolesc. Med. 2000; 154: 763-70.